Gene Silencing Holds Promise for Treating Hereditary ATTR Amyloidosis
A novel therapeutic approach which exploits the normal biological process of gene silencing, or RNA interference (RNAi), is continuing to show promise as a potential treatment for hereditary ATTR (hATTR) amyloidosis. Results presented recently at the 1st European ATTR Amyloidosis...
Read More
Mazen Hanna
Physician Spotlight: Dr. Mazen Hanna
Dr. Mazen Hanna is a cardiologist and current co-director of the Amyloidosis Program at the Cleveland Clinic alongside hematologist, Dr. Jason Valent. He has been a member of the heart failure and cardiac transplant unit in the department of cardiovascular...
Read More
Northern California Support Group and Patient’s Day Hosted by Prothena
The Northern California Amyloidosis Support Group which meets quarterly every year, held their 14th annual anniversary meeting in July in South San Francisco.  The event was hosted by the team at Prothena and was a very successful Patient’s Day event...
Read More
Cardiac AL Amyloidosis Patients Experience Delays in Diagnosis
A survey of patients with all forms of cardiac amyloidosis and their caregivers was conducted in order to understand delays, errors, and inconsistencies in the diagnostic pathway for patients with cardiac amyloidosis and validated using caregiver responses. Data from AL...
Read More
scott gottlieb.jpg
The New FDA Commissioner
Dr. Scott Gottlieb was appointed the new commissioner of the Food and Drug Administration (FDA) on May 11, 2017. He is a physician and a cancer survivor, having been successfully treated for Hodgkin’s lymphoma. Gottlieb has previously commented that the...
Read More

320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170

ARC is a 501(c)(3) nonprofit organization